New hope for bile duct cancer: targeted combo targets hard-to-treat gene mutation
NCT ID NCT07282262
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a precision medicine approach for people with advanced biliary tract cancer that has a specific IDH1 gene mutation and has stopped responding to standard chemotherapy. About 300 participants will receive a combination of ivosidenib (a targeted pill) plus either lenvatinib or an immunotherapy drug. The goal is to see if this combination can shrink tumors or slow cancer growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Peking Union Medical College Hospital Outpatient Department
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••